公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2019 | Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014) | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. | Journal of Hepatology | 1 | 9 | |
2020 | Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial | Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU | JAMA Oncology | 742 | 646 | |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 171 | 154 | |
2017 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. | The Lancet | 3010 | 2816 |